
Cutaneous T‐cell lymphoma (CTCL) are a rare group of cancers that develop in the skin from T cells (a type of white blood cell). Mogamulizumab is a promising treatment for CTCL, but its most common adverse effect is a drug rash named mogamulizumab‐associated rash (MAR). MAR remains poorly described, and it is difficult to tell apart from CTCL itself. In this study, we reviewed past records and followed up with all 24 patients with CTCL who were treated with mogamulizumab since it was approved for use in 2018 and seen by our institution in the USA. We saw a higher rate of MAR among our patients (71%) than previously reported, however, most of our patients had a specific type of CTCL (Sézary syndrome)...
Like
Save
Share